WINTON GROUP Ltd Makes New Investment in Bausch Health Companies Inc. (NYSE:BHC)

WINTON GROUP Ltd bought a new position in Bausch Health Companies Inc. (NYSE:BHCGet Rating) during the 2nd quarter, Holdings Channel.com reports. The firm bought 31,647 shares of the company’s stock, valued at approximately $265,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in BHC. WASHINGTON TRUST Co bought a new stake in Bausch Health Companies in the first quarter valued at $28,000. First Horizon Advisors Inc. boosted its holdings in Bausch Health Companies by 85.1% in the second quarter. First Horizon Advisors Inc. now owns 5,607 shares of the company’s stock valued at $45,000 after acquiring an additional 2,578 shares in the last quarter. Assetmark Inc. lifted its position in Bausch Health Companies by 454.3% during the second quarter. Assetmark Inc. now owns 10,421 shares of the company’s stock valued at $87,000 after buying an additional 8,541 shares during the period. XR Securities LLC purchased a new position in Bausch Health Companies during the second quarter valued at $91,000. Finally, Range Financial Group LLC lifted its position in Bausch Health Companies by 11.5% during the second quarter. Range Financial Group LLC now owns 12,013 shares of the company’s stock valued at $100,000 after buying an additional 1,237 shares during the period. Institutional investors own 70.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Piper Sandler decreased their target price on Bausch Health Companies from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Friday, September 9th. Truist Financial downgraded Bausch Health Companies from a “buy” rating to a “hold” rating in a research note on Thursday, July 28th. Royal Bank of Canada upped their price objective on Bausch Health Companies from $4.50 to $8.00 and gave the stock a “sector perform” rating in a report on Thursday, September 1st. StockNews.com initiated coverage on Bausch Health Companies in a report on Wednesday, October 12th. They set a “hold” rating on the stock. Finally, JPMorgan Chase & Co. lowered Bausch Health Companies from an “overweight” rating to a “neutral” rating in a report on Thursday, July 28th. Five analysts have rated the stock with a hold rating, According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $10.60.

Bausch Health Companies Stock Up 0.1 %

Shares of BHC opened at $7.57 on Monday. The company has a current ratio of 1.05, a quick ratio of 0.77 and a debt-to-equity ratio of 48.05. The stock’s 50 day moving average is $7.03 and its two-hundred day moving average is $7.67. The firm has a market cap of $2.74 billion, a P/E ratio of 10.81, a PEG ratio of 0.13 and a beta of 0.99. Bausch Health Companies Inc. has a 12 month low of $4.00 and a 12 month high of $28.35.

About Bausch Health Companies

(Get Rating)

Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.

Read More

Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc. (NYSE:BHCGet Rating).

Institutional Ownership by Quarter for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.